Selecting haematological malignancy patients for intravenous immunoglobulin | Zendy

Paxton L. | Zendy; Hawkins C. | Zendy; Crispin P. | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Selecting haematological malignancy patients for intravenous immunoglobulin

Author(s) -

Paxton L.,

Hawkins C.,

Crispin P.

Publication year - 2016

Publication title -

internal medicine journal

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.596

H-Index - 70

eISSN - 1445-5994

pISSN - 1444-0903

DOI - 10.1111/imj.13205

Subject(s) - medicine , malignancy , antibody , intravenous immunoglobulin therapy , retrospective cohort study , immunoglobulin g , intensive care medicine , immunology

Prior randomised studies of immunoglobulin replacement therapy have studied mixed populations with or without a history of infections. Immunoglobulin therapy is expensive and in limited supply suggesting that optimising patient selection is of value. In this retrospective study, infection history identified high‐risk groups benefiting from treatment. A group of patients without any infection history had a low risk of infection without immunoglobulin.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research